You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科-B(06622.HK):國家藥監局批准環孢素A眼凝膠第III期臨牀試驗的新藥臨牀試驗申請
格隆匯 08-12 08:07

格隆匯8月12日丨兆科眼科-B(06622.HK)發佈公吿,中國國家藥品監督管理局(“國家藥監局”)已批准公司的環孢素A眼凝膠用於治療中重度乾眼症的新藥臨牀試驗申請(“新藥試驗申請”)。該項第III期臨牀試驗乃遵照藥品審評中心於2023年9月發佈的《乾眼治療藥物臨牀試驗技術指導原則》所載規定設計。

此外,NVK002(公司核心產品之一)用於治療近視、為期兩年的第III期臨牀試驗(“China CHAMP”)已於2024年8月5日完成最後一名患者的最後一次訪視。China CHAMP的主要目標為評估NVK002(0.01%及0.02%的低劑量阿托品)對治療中國兒童及青少年近視加深的療效及安全性。該項試驗涉及18間中心,入組777名患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account